Mark Newman, Author at Endocrine News

President's Viewpoint

Early-Career Members Grow Careers Through Our Professional Development Programs

Spring in the northern hemisphere is a time of exploration, growth, and transition. That’s why I’m excited this month to highlight our Society programs that help rising clinicians and researchers explore, grow, and transition to careers in endocrinology. One of our newer programs is the Medical School Engagement Program (MSEP), which in April will welcome...

Pharma Fridays

Pharma Friday – April 10, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amgen Announces Positive Top-Line Phase 3 Results for TED Treatment On April 6, Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active thyroid...

Hyperinsulinemia Emerges as Critical Predictor of Severe Liver Outcomes

Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular...

Diabetes News and Research

Continuous Glucose Monitoring Cuts Readmission Risks

A new prospective study has found that initiating continuous glucose monitoring (CGM) at the point of hospital discharge is associated with significantly improved glycemic control and may halve the risk of hospital readmission for patients with type 2 diabetes. The research, published in Journal of the Endocrine Society, suggests that providing patients with real-time data...

Bone and Mineral

Beyond the Curve: How XLH Impacts Skeletal Maturation and Predicted Height

New clinical research has identified a significant delay in skeletal maturation among children with X-linked hypophosphatemia (XLH), with male patients experiencing notably more pronounced delays than females. The study, published in Journal of The Endocrine Society, highlights a significant gap between chronological age and bone age (BA). These findings provide clinicians with more precise benchmarks...

Advocacy
- Clinical
- Research

Endocrine Society Advocacy Update – April 2026

Each month, Endocrine News presents an overview of how the Endocrine Society has been advocating for the practice and science of endocrinology, both in the U.S. and around the world. Endocrine Society Calls on Congress to Increase NIH Funding and Protect Research Because Congress is considering funding for fiscal year 2027 right now, the Endocrine Society organized a virtual Hill Day on...

Pharma Fridays

Pharma Friday – April 3, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Foundayo™ Weight Loss GLP-1 Pill On April 1, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet...

Obesity

Could Moving Obesity Diagnosis Beyond BMI Delay Treatment?

Endocrine Society shares concerns with The Lancet’s obesity framework Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health problems may complicate diagnosis and delay treatment, according to an Endocrine Society guideline communication published in The Journal of Clinical Endocrinology & Metabolism. “How obesity is...